Top 50 Life Science Startup Investors in Switzerland in July 2025
A list of 50 angel investors and VC (Venture Capital) funds that invest in Life science startups based in Switzerland. We rank investors based on the number of investments they made in Life science companies from Switzerland. We update this investor list every month.Top 50 Life Science Startup Investors in Switzerland in July 2025
Zürcher Kantonalbank - as an independent, incorporated public-law institution - is wholly owned by the canton of Zurich.
Show more
Investment focus
- Health Care, Medical Device, Biotechnology
- Seed, Series A, Funding Round
- Switzerland, Japan, Spain
Portfolio highlights
- askEarth — We are your experts in satellite imagery (Earth Observation) and large language models (LLMs)
- DPhi Space — DPhi Space is a startup that specializes in shared satellites for hosted payloads to simplify access to space. The company's flagship product, Clustergate, is a modular platform that aggregates multiple payloads—such as sensors, antennas, or cameras—into a single container, allowing them to share a satellite. This approach reduces costs andcomplexity by optimizing satellite resources. Clustergate offers built-in in-orbit computing, AI processing, and real-time data analytics, enabling businesses to deploy and manage their technology in space without requiring specialized expertise.
- Eleven Dynamics — Eleven Dynamics is a developer of software technology designed to automate industry quality control. The technology software provides solutions for designing and simulating. The processes include automatically programming measurement paths at optimal process time without the need for being a robotic expert, connecting all hardware in real time, andexecuting the measurement process. The software is used to create custom robotic solutions for clients.
Eclosion assists entrepreneurs with the necessary resources to bridge the gap between their laboratories and the stage where the start-up
Show more
Investment focus
- Biotechnology, Pharmaceutical, Health Care
- Seed, Series C, Funding Round
- Switzerland
Portfolio highlights
- KYLYS — KYLYS is an innovative Swiss company based in Geneva founded in March 2017. KYLYS provides people and patients with highly effective and safe products based on biomolecules.
- Genkyotex — Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.
- MPC Therapeutics — MPC Therapeutics develops a novel class of compounds with application in Immunotherapy and Metabolic diseases
The Foundation for Technology Innovation gives financial assistance to creative and technological projects at various phases of development. FIT funds projects in energy and the environment, information and digital technology, life sciences and health, precision industries, and nutrition and agriculture.
Show more
Investment focus
- Health Care, Biotechnology, Information Technology
- Debt Financing, Grant, Seed
- Switzerland, France
Portfolio highlights
- INERGIO — This EPFL spin-off is developing faster, portable energy units that offer ten times the power at half the weight of current technology. Founder Mahmoud Hadad’s fuel cell innovation, which uses standard butane or propane that’s safe and available worldwide, offers high autonomy. INERGIO’s fuel cell geometry allows unlimited scaling, making thetechnology suitable for applications ranging from charging consumer electronics to auxiliary power for drones to automobile fuel cells. The team has a working prototype and is looking to have its minimal viable product by summer 2020 to start the pilot project with potential partners and customers.
- Brightank — Catalyzing your Decarbonization. Brightank accelerates decarbonization with ammonia cracking catalysts, turning ammonia into fuel for heavy transport, hydrogen supply, and power. EPFL spin-off
- DigeHealth — DigeHealth's approach to monitoring gut health using bowel noises and body measurements could provide some really valuable insights into digestive well-being.
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- United States, Switzerland, Canada
Portfolio highlights
- Granite Bio — Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.
- Helicore Biopharma — Helicore Biopharma is at the forefront of developing cutting-edge treatments for obesity and related disorders.
- Light Horse Therapeutics — Light Horse Therapeutics is the gene editing applied to small-molecule drug discovery, pioneering approaches to target the root causes of disabling and life-threatening diseases. Its advanced platform identifies cryptic chemically accessible functional domains within targets that are critical in disease biology. Our initial focus addresseshigh-value, historically challenging oncology targets with the opportunity to apply the technology to other therapeutic areas in the future.
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates.
HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more
Investment focus
- Biotechnology, Health Care, Software
- Seed, Convertible Note, Pre-Seed
- United States, India, United Kingdom
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.
Show more
Investment focus
- Health Care, Software, Biotechnology
- Series A, Seed, Series B
- Switzerland, France, Germany
Portfolio highlights
- Metafuels — Our breakthrough sustainable aviation fuel (SAF) technology, aerobrew™, will make affordable net-zero aviation a reality. The technology is innovative, highly scaleable and able to tap into future global renewable energy systems efficiently. Starting from renewable feedstocks including green hydrogen, driven by renewable electricity, andsustainably sourced CO2, for example from direct air capture, aerobrew™ provides an efficient route to large-scale production of e-kerosene, overcoming the scale up challenges and high costs of alternative e-fuels technologies. aerobrew™ is also compatible with the biogenic route whereby the carbon required for the process is derived from renewable and sustainable cellulosic biomass which, does not compete with the food chain (wood, miscanthus, etc.). With a high carbon conversion, high selectivity and a high overall SAF yield, aerobrew™ leads to attractive production economics and cost leadership. With a rapidly growing demand for SAF, aerobrew™ stands to contribute significantly to the decarbonisation of global aviation and to support the achievement of net zero 2050 targets.
- Poppins — Mila merges music, technology, and neuroscience to reshape therapy into a musical experience. We create musical games for children based on neurologic music therapy methods. These games are designed to address learning dissabilities like dyslexia, providing a digital treatment at home and helping identify these conditions. Behind these games, weleverage data science and new technologies to interpret learning, language, and motor performance into a cognitive score. Our goal is to improve the process for patients receiving treatment and to reaching the vast undiagnosed majority.
- Orakl Oncology — Cultivated with love by the Orakl team.
Boosting health pioneers. We invest in early stage start-ups in different sectors: medtech, life science, biotech, mental health, public health, well-being.
Show more
Investment focus
- Medical, Health Care, Biotechnology
- Seed, Series A
- Switzerland
Portfolio highlights
- Testmate Health — 2 in 1 urine test with immediate results for Chlamydia trachomatis and Neisseria gonorrhoeae. Results within minutes & 100% anonymous.
- Limula — Limula provides a unique platform technology enabling scale out of cell therapy production. By bringing manufacturing closer to the patients, our solution will broaden access to these highly personalised treatments. Our patented solution is composed of an automation unit and single use kits, allowing healthcare providers to safely manufacture CGTin a decentralized manner. We support companies at all stages of the cell therapy life cycle, from R&D to routine production.
- SEITO Biologics — SEITO Biologics AG develops innovative IL-2 immunotherapies that preferentially activate T regulatory (Treg) cells, while sparing cytotoxic effector immune cells.
The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise,entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.
Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.
Show more
Investment focus
- Software, Biotechnology, Information Technology
- Seed, Series A, Funding Round
- Germany, Switzerland, United States
Portfolio highlights
- Eyeo — eyeo revolutionizes imaging with color splitter sensors. Capture sharper, brighter images in low light using optical waveguide innovation, discover how it works
- nuuEnergy — nuuEnergy is a tech-enabled solution aiming to revolutionize the heat pump installation industry. By leveraging technology and industry expertise, we streamline the purchasing and installation process. Our unique approach, refinanced through innovative strategies, promotes a self-reliant and carbon-neutral lifestyle for all our customers.
- Steuerboard — Steuerboard serves as a collaborative platform facilitating digital interaction between tax advisors and clients. The mission of Steuerboard is to rethink the way accountants and clients work together.
BlueOcean Ventures SA provides capital, operational and company development advisory support (mentoring, company management, divestment experience, network, negotiation support) to entrepreneurs in Switzerland.
BlueOcean Ventures is based in Geneva, Switzerland.
Show more
Investment focus
- Health Care, Medical, Biotechnology
- Series A, Seed, Series B
- Switzerland, India, France
Portfolio highlights
- nPloy — Simply set your filters and get matched with your dream job! Let top employers apply for you & connect with them via chat or a video call.
- CyanoGuard AG — Our award-winning cyanide testing and optimizing solution is ideal for the mining, food, and medical field. It's easy to use, digital and offers real-time data.
- 99RetailStreet — 99RetailStreet is an eCommerce Cloudplatform for the unorganized Retail business in the developing countries. Our ecosystem targets Retailers, Distributors, and Manufacturers. 99RetailStreet provides POS solutions to Retailers, Real-Time Analytics to Manufacturers and Distributors
We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, Switzerland, United Kingdom
Portfolio highlights
- Windward Bio — Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field.
- Alleviant Medical — Interventional therapy for congestive heart failure
- Callio Therapeutics — Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits.
Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, The Netherlands, Switzerland
Portfolio highlights
- Perfuze — Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. Perfuze is located within Galway City in the West of Ireland. The founders have over 30 years combined medtech experience within start-up and large corporations.Perfuze is developing innovative medical technology to treat acute ischemic stroke.Perfuze is developing innovative cathetertechnology to treat acute ischemic stroke. Their technology is intended to provide superior clinical outcomes in shorter procedural times; resulting in safe, cost-effective therapy. Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. The founders have over 30 years combined medtech experience within start-up and large corporations. Perfuze is currently located in the Business Innovation Centre on the campus of the National University of Ireland, Galway, and is in the process of relocating to the IDA Business Park in Dangan, Galway.
- Avidicure — Avidicure is developing dual agonistic avidity-engineered multifunctional antibodies, AVC-Boosters, as monotherapy for treatment of cancer
- Atalanta Therapeutics — Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases.
Vinci Capital is a leading Swiss private equity firm with over MCHF 200 under management. Since 1998 they have provided equity to over 30 Swiss technology and industrial companies to finance innovation, growth and succession-buyouts.Their investment team capitalizes on 40 years of cumulated experience in private equity and a solid operationalbackground in growth, turn-around, consolidation, IPOs and M&A situations.
Show more
Investment focus
- Medical, Health Care, Biotechnology
- Series A, Series B, Funding Round
- Switzerland, Germany
Portfolio highlights
- Anergis — Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne inSwitzerland.
- SENSIMED — Sensimed designs, develops, and commercializes integrated micro-systems for medical devices. The company’s product portfolio includes SENSIMED Triggerfish, a product that offers an automated recoding of continuous ocular dimensional change over 24 hours. Sensimed is now focused on expanding the knowledge of how this individual data can best beused in the clinical setting to deliver customized treatment. The 24 hour profiles are being centralized on a registry together with patient and treatment information. The data is being analyzed and modeled on an ongoing basis in an attempt to identifying pathological patterns that can be used to differentiate indication, personalize treatment and assess efficacy following treatment.Sensimed was founded by Matteo Leonardi and Sacha Cerboni in August 2003 and is based in Lausanne, Switzerland.
- Beqom — beqom is a Total Compensation Management Software Solution focused exclusively on managing compensation & performance for HR & Sales.
Kinled was founded in 1980 to retain the investment assets of the Aisher family.In 1990, the investment focus shifted to a portfolio of early stage investments applying Kinled’s company development experience alongside the endurance and passion of family owned investments together with the strategic focus of venture capitalists.Since then,Kinled has taken 8 companies to public markets and many more to successful trade sales at significant multiples.
Show more
Investment focus
- Biotechnology, Health Care, Financial Services
- Seed, Funding Round, Series A
- United Kingdom, United States, Switzerland
Portfolio highlights
- Xapien — Xapien delivers automated insight reports on companies and individuals in minutes, so you can make informed business decisions quickly and with confidence.
- OneTrust — OneTrust is a provider of privacy management and marketing compliance technology that helps organizations comply with global regulations. It automates privacy impact assessments and data inventory mapping, enforces risk remediation actions, and triggers recurring audits for continuous compliance monitoring across customer, employee, and vendor datatransfers. Its web-based software can be accessed on any device and provides a single place for a private office to collaborate with business groups, vendors, and trusted advisors managing privacy risks. The result is the ability to demonstrate privacy by design and ongoing compliance with policies, data privacy laws (GDPR, BCR, Privacy Shield), and other privacy frameworks (HITECH, ISO, GAPP, APEC).The company was founded in 2016 and is headquartered in Atlanta, Georgia.
- Connect Earth — Connect Earth is an environmental data company that builds the infrastructure for climate-conscious products by aggregating and standardising environmental data and making it available through developer-first toolkits. The core product is an API solution that calculates the carbon impact of spend-based financial transactions of consumers and companies.
Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Funding Round, Series B, Series A
- Denmark, Sweden, Switzerland
Portfolio highlights
- Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
- Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
- Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.
Rheingau Founders is a Berlin&Munich based Venture Capital firm active since 2011. Focusing on pre-seed to Series A investments in Europe, predominantly B2B in the fields of Marketplaces, Software as a Service, InsurTech, and eHealth. Rheingau targets start-ups that have the potential to sustainably disrupt existing processes and value chains.Besides the financial investment, we offer strategic support through the mentorship of our partners.
Show more
Investment focus
- Software, E-Commerce, Internet
- Seed, Series A, Pre-Seed
- Germany, United States, Poland
Portfolio highlights
- MoleQlar — MoleQlar is a data and research-driven longevity company. It provides valuable information and offers consumers lab-tested nutritional supplements. The company focuses on functional medicine with optimized nutrition. Their product range includes Uthever NMN, Resveratrol, Betaine, Carnosine, and more. These products are aimed at lowering biologicalage and promoting health and longevity. MoleQlar also offers health tracking services. The company is certified in Germany and delivers its products EU-wide, including Switzerland.
- Qualifyze — Qualifyze (former ChemSquare) was founded out of the Technical University of Darmstadt in September 2017. Today, we are based in Frankfurt am Main, the heart of Germany’s pharmaceutical cluster, where the leading life science companies are based. Our team consists of 16 people with diverse backgrounds and areas of expertise in business,engineering, and technology as well as several strategic partners from the pharma, food and cosmetics industry.
- Akhetonics — Creating the first all-optical RISC Processor
Fongit Seed Invest (FSI) is the leading Seed Money Fund of Switzerland for young technology companies. It provides smart seed capital.
Show more
Investment focus
- Health Care, Medical, Biotechnology
- Seed, Series A, Series B
- Switzerland
Portfolio highlights
- EBAMed — EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware andsoftware components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.
- Gmelius — Gmelius is the world's first 360 email collaboration platform designed for Gmail and your company's daily apps. Join the async movement!
- Annaida Technologies — Annaida Technologies has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies.
Backing engineers building awe, wonder, speed.
Show more
Investment focus
- Software, Biotechnology, Health Care
- Pre-Seed, Seed, Funding Round
- United States, United Kingdom, France
Portfolio highlights
- Yakoa — Content creation is now AI-native. If your digital rights system isn't, it's holding you back. Discover our solutions.
- Modelwise — Automated functional safety analysis via drag & drop. Seamless Integration. Faster Analyses. Zero Defects. More Savings.
- Fluent Metal — Fluent Metal is a company that makes metal 3D printing economical, efficient, and safe.
BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- Switzerland, Germany, France
Portfolio highlights
- ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
- TOLREMO therapeutics — TOLREMO therapeutics is striving to prevent the development of cancer therapy resistance through its proprietary drug discovery and development platform. Learn more about us.
- Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.
Show more
Investment focus
- Health Care, Biotechnology, Pharmaceutical
- Series A, Series B, Seed
- France, Switzerland, Spain
Portfolio highlights
- Poppins — Mila merges music, technology, and neuroscience to reshape therapy into a musical experience. We create musical games for children based on neurologic music therapy methods. These games are designed to address learning dissabilities like dyslexia, providing a digital treatment at home and helping identify these conditions. Behind these games, weleverage data science and new technologies to interpret learning, language, and motor performance into a cognitive score. Our goal is to improve the process for patients receiving treatment and to reaching the vast undiagnosed majority.
- Memo Therapeutics — Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
- Vico Therapeutics — Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.
VI Partners are Venture Capitalists successfully financing outstanding teams and innovations in the Healthcare and Technology space since 20 years.
Show more
Investment focus
- Health Care, Biotechnology, Medical Device
- Series A, Series B, Series C
- Switzerland, Germany, United States
Portfolio highlights
- Xeltis — Xeltis is pioneering a restorative approach in cardiovascular therapy.
- LeaseTeq — LeaseTeq bietet Privat- sowie Unternehmenskunden das erste komplett digitale Leasingangebot.
- Unique — Try Unique Finance GPT to increase productivity by automating manual workload through AI and ChatGPT solutions.
Heritage Bank
Show more
Investment focus
- Biopharma, Life Science
- Seed
- Switzerland
Portfolio highlights
- Lagosta — WHAT WE DO. At LAGOSTA, we take great care in sustainably farming the European spiny lobster, converting byproducts in unique highly valuable products and setting up a series of ecological programs. Accelerated depletion of wild stocks due to overfishing and
Primal Capital, an independent venture capital " incubator bait fund at ", served as the Associate than July 2012 Hiroshi was Sasaki is the venture capital fund that serves as the representative partner. Representative of Sasaki, the seed acceleration program "Incubate Camp" operated by Incubate bait fund is carried out a totalof four times of planning and management than in 2012, They have also engaged in support operations of portfolio companies. - See more at: https://www.crunchbase.com/organization/primal-capital#sthash.m2z1DCbt.dpuf
Show more
Investment focus
- Software, Information Technology, Internet
- Seed, Funding Round, Pre-Seed
- Japan, Spain, Switzerland
Portfolio highlights
- Hivello — Hivello is a Decentralized Physical Infrastructure Network aggregator. Contribute resources, connect with Web3 protocols, and effortlessly generate passive income.
- RemitAid — RemitAid is a fintech company that operates an overseas payment platform for cross-border transactions between companies.
- xCARE — xCARE specializes in the development and commercialization phases of the pharmaceutical and medical device industries.
Beat Schillig - Founder @ Venture Kick
Show more
Investment focus
- Information Technology, SaaS, Music
- Seed, Series A
- Switzerland
Portfolio highlights
- TYXIT — TYXIT is linking musicians wirelessly without configuration, allowing a personal audio monitoring.
- PXL Vision — PXL Vision enables state-of-the-art digital identity verification. PXL Vision's highly flexible technology solution helps global customers build trust digitally...
- 1Drop Diagnostics — 1Drop Diagnostics is a cutting edge medical diagnostics and life science company. They combine the best techniques from microfluidics, biochemistry, photonics and information technology to build high performance point-of-care diagnostics devices.Their vision is to provide high quality medical information for everyone. They aim to increase accessto quality healthcare by providing laboratory quality, easy to use, medical diagnostics in any setting. The 1Drop Diagnostics system is being developed for a broad menu of clinical applications including multiplexed assays of proteins, nucleic acids and peptides. Their first clinical applications are in the screening, diagnostics and monitoring of cardiovascular disease and infectious disease.Their mission is to improve patient lives by enabling precision medicine through non-invasive diagnostic tests providing actionable health information that is accessible to everyone at any time. They facilitate the early detection, prevention and management of disease. They empower people to live better lives.
For more than 35 years, Nest, as the first ecological and ethical pension fund in Switzerland, has remained true to its guiding principle: the optimal provision for the companies affiliated with us and their employees.
Show more
Investment focus
- Health Care, Biotechnology, Medical
- Seed, Series A
- Switzerland
Portfolio highlights
- Piomic — There are about 50 million reported cases of patients suffering from hard-to-heal wounds, which has created a severe cost burden on global healthcare systems.The COMS® One Therapy System is a portable, hand-held device which incorporates the technologies for optical and magnetic stimulation, intended to promote wound healing in chronic leg andfoot ulcers.The pivotal clinical study showed that the treatment is safe, leads to accelerated wound closure, overall reduced pain and increased quality of life. The easy-to-use, single button operated device integrates smoothly into the patient’s healing journey with usage in stationary and ambulant facilities but also in patient’s home.By developing a therapy which is safe and effective we hope to set a better future for patients in need.
- Comphya — CaverSTIM is a novel implantable device able to restore natural penile erection by neuromodulation.
- Nagi Bioscience — Enabling small organisms testing to any lab. Unleash unique datapoints efficiently at a high-throughput rate.
Bruker Corporation is a provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis.
Show more
Investment focus
- Biotechnology, Medical, Health Care
- Series A, Funding Round, Seed
- United States, Switzerland
Portfolio highlights
- KIYATEC — Kiyatec is a functional precision oncology company that measures the response of individual patient live cancer cells with its innovative 3D cell culture technology platform. Kiyatec works with leading biopharmaceutical companies to unlock response dynamics for investigational drug candidates for use in solid tumors.
- Terrain Bio — Terrain Bio helps RNA therapeutics companies design and build better RNA, faster. Leveraging the latest innovations in protein and RNA design and the deep expertise of its scientific cofounders, Terrain brings unparalleled speed and quality to RNA manufacturing.
- Mercy BioAnalytics — We are making early stage cancer 100,000x easier to find using extracellular vesicles found in blood, specific to their parent cells.
Medicxi is an investment firm that focuses on the life sciences sector. It was established in 2016 by the former Index Ventures life sciences team, who have been active for over 20 years and have significant experience in drug discovery and the development of therapeutics for unmet medical needs.
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series A, Series B, Seed
- United States, United Kingdom, The Netherlands
Portfolio highlights
- Curevo — focused on a new generation of adjuvanted subunit vaccines Learn More Our Focus We're dedicated to developing non-mRNA vaccines for unmet medical needs Curevo Vaccine is a clinical-stage biotech company dedicated to developing next-generation non-mRNA vaccines. We focus on one need at a time, allowing us to bring effective and better-tolerated vaccines to market quickly
- Rapt Therapeutics — RAPT Therapeutics is a clinical-stage biopharmaceutical company driven by our mission to treat inflammatory and immunologic diseases. Our cutting-edge science is fully focused on developing therapeutics that intelligently target key drivers of the immune system to transform the treatment of inflammatory and immunologic diseases, and improve and empower countless lives. Join us in our quest.
- Ottimo Pharma — Ottimo Pharma is a private biotechnology company dedicated to enhancing cancer treatment outcomes and minimizing the overall healthcare burden.
RH Capital a Rhia Ventures fund, is an impact-first venture capital firm that invests in early-stage startups with the potential to transform women's health and increase health equity.
Show more
Investment focus
- Health Care, Biotechnology, Health Diagnostics
- Funding Round
- United States
Portfolio highlights
- Eli — Eli empowers women to understand their body and the transitions it goes through every day, and across life. We develop a device that uses saliva to capture hormone fluctuations at home, and an app that gives women the information they want to own their health decisions.
- Novocuff — Novocuff is a medical device firm that aims to improve pregnancy outcomes and reduce preterm deliveries caused by PPROM and cervical shortening.
- Seven Starling — Seven Starling offers comprehensive online care for postpartum mental health. Take the free assessment to get started.
MedHoldings operates as a venture capital and private equity firm.
MedHoldings focuses primarily on development and late-stage medtech ventures in Switzerland, Europe, and emerging markets. The company conducts its business in Switzerland.
Show more
Investment focus
- Medical, Health Care, Life Science
- Series A
- Switzerland
Portfolio highlights
- Abionic — Abionic SA is ideally positioned at the boundaries of medical technology, biotechnology and nanotechnology. As a spin-off from EPFL (Swiss Federal Institute of Technology Lausanne, Switzerland), Abionic uses these highly advanced technologies to provide the medical profession with a novel diagnostic tool designed to give patients personal allergyprofiles. Abionic aims to become an important international player in the field of personalized medicine, in particular in allergy detection.Abionic SA is a certified ISO 9001/13485 company, including research, development and commercialization of in vitro diagnostic devices for allergies detection. The standard ISO 13485 specifies requirements for a quality management system where an organization has to demonstrate its ability to provide medical devices and related services that consistently meet customer and regulatory requirements.Abionic SA is a privately owned high-tech company and is strongly supported by the Swiss Federal Institute of Technology of Lausanne (EPFL), The Canton of Vaud and Venturelab.Abionic was founded by former scientists from the biomedical optics laboratory (LOB) at EPFL. Its headquarters are located in Lausanne, Switzerland.Abionic appreciates the support it has received from:
Primal Capital is an early stage and growth investor in Web3 and emerging technology companies. Our current portfolio consists of 50+ investments in Web3 & blockchain applications focused on consumer and enterprise adoption.
Show more
Investment focus
- Blockchain, Information Technology, Artificial Intelligence
- Seed, Pre-Seed, Series A
- United States, United Kingdom, Switzerland
Portfolio highlights
- Agents World — Agents World operates as an web3 AI firm.
- Fountain — Fountain operates in the finance industry, providing a wallet platform specifically designed for teams. The platform allows users to create permission-controlled wallets in a matter of seconds, offering a centralized location for managing all transactions and treasury. In addition to its wallet services, Fountain also offers a unique way to enjoypodcasts, further diversifying its product offerings. With a team of six, Fountain continues to innovate in the realm of finance and entertainment.
- Ooga Booga — Ooga Booga is a liquidity aggregator designed to support the goal of becoming the most capital efficient blockchain.
Swiss ICT Investor Club (SICTIC) connects smart money investors to Swiss seed and early-stage tech startups.
Show more
Investment focus
- Software, Artificial Intelligence, Information Technology
- Seed, Pre-Seed, Funding Round
- Switzerland, Germany, United Kingdom
Portfolio highlights
- Pelt8 — Pelt8 enables climate action through the platform with scalable processes and controls to collect sustainability-related data in an easy and traceable way.
- Creaitor — Creaitor is the ultimate solution for content producers, offering a comprehensive suite of AI tools and integrated SEO features. Streamline your content creation process and optimize your online presence with our powerful platform.
- Health Yourself — Health Yourself is making routine healthcare services available digitally and from home. So far, we are offering lab tests from home, medication subscriptions and personalised supplements for health concerns ranging from sexual health to prevention.
The EU framework programme for research and innovation
Show more
Investment focus
- Biotechnology, Health Care, Software
- Grant, Seed, Funding Round
- Spain, Switzerland, United Kingdom
Portfolio highlights
- NovaMea — NovaMea is a cleantech startup that designs and commercializes electrochemical systems for energy storage and conversion.Its purpose is to create technology, services, and products for the storage and conversion of energy using electrochemical processes, as well as to produce, store, sell, and distribute these products and their components.
- Perciv AI — Perciv provides artificial intelligence (AI)-based software solutions to unlock the latent possibilities of radars and allow resilient and economical autonomous systems with Lidar-like performance even in severe weather circumstances.
- Neuron Soundware — Neuron Soundware uses Artificial Intelligence and Machine Learning in combination with the analysis of sound and other physical parameters.
Lukas Speiser is the founder and CEO of Amorana.ch
Show more
Investment focus
- Wellness, Nutrition, Health Care
- Seed
- Germany, Switzerland
Portfolio highlights
- feey — feey is a houseplant shop. They offer plants that include entry-level plants, baby plants, animal-friendly plants, large plants, home office plants, hanging plants, aglaonema, alocasia, calathea, hoya, monstera, and philodendron.
- Sleepiz — Sleepiz is a Zürich based startup with the aim to enable the medical community to take healthcare into the home environment. Sleepiz provides an easy and comfortable to use solution with a device that is simply placed on the bedside table. The device operates in a non-contact fashion and measures movements originating from heart contractions andbreathing patterns as well as body motions with medical grade accuracy.By making use of wireless millimeter wave technology, sensor fusion and artificial intelligence Sleepiz will in the future not only able to diagnose sleep disorders, but also to perform long-term monitoring. Thereby, the progression of chronic diseases can be monitored to allow faster intervention and better treatment.
- Dunatura — Dunatura engages in the manufacture and supply of vitamins and micronutrients.
NEXT VENTŪRES is a venture capital firm that invests in the sports, fitness, health, and wellness markets. With established expertise and deep connections in these markets as well as proven financial track records, the NEXT VENTŪRES team is well positioned to create significant value for their investors and their portfolio companies.The firm wasestablished in 2018 and is based in San Francisco, CA
Show more
Investment focus
- Health Care, Wellness, Medical
- Seed, Series A, Series B
- United States, Canada, Finland
Portfolio highlights
- Pair Team — Pair Team is on a mission to build the primary care infrastructure for America’s most vulnerable communities.They are the first tech-enabled care team that empowers safety-net primary care systems and the Medicaid & Medicare patients they serve. They act as an extension of the clinical staff to provide a personalized, high-touch careexperience while addressing patients' barriers to care such as lack of transportation, housing/food insecurity, and mobile phone access. Internally, they are building a unique care delivery platform to ensure clinical best practices, integrate care with community-based organizations, and automate administrative work so that clinicians can focus on time with our patients.
- Eternal — Eternal offers lifetime athletes an expert team of health and performance experts to help them stay active in the sports they like for as long as possible.
- Eternal — With a mission to keep athletes active and thriving in their chosen sports for as long as possible, Eternal provides members with a holistic understanding of their health, fitness, and benchmarks for key markers of the aging process along with guidance from high-performance care teams to support every stage of an athlete’s journey.
Idinvest Partners is a pan-European private equity manager focused on the low and middle-market segments. With over 6 billion euros under management, the company has developed several complementary areas of expertise, including equity investments in buyout deals focusing on both mid-size as well as young innovative European companies; primaryinvestments in European private equity funds focusing primarily on the middle market segment; secondary investments; mezzanine investments in Europe; and private equity consulting.Idinvest Partners’ recent success stories include Criteo, Clear2Pay, Meetic, Prosensa, Converteam, Kwik Fit, Lastminute.com, Dailymotion, Deezer, Talend, Synthesio, Menlook, Vestiaire Collective, Pretty Simple, Curse.com, Withings, Kantox, Secret Escapes, Happn, Peakon, Dayuse, Botify, Financefox, Azalead and many more.
Show more
Investment focus
- Biotechnology, Software, Health Care
- Series B, Series A, Funding Round
- France, United States, Spain
Portfolio highlights
- Corti — Corti offers a digital assistant, augmenting medics in improving patient outcomes and internal performance.
- Coave Therapeutics — Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.
- BreezoMeter — BreezoMeter offers personalized air quality & pollen data as well as active fire alerts with worldwide coverage & accuracy down to the street level.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- United States, Denmark, United Kingdom
Portfolio highlights
- Supira Medical — Next Generation Solution for Temporary Mechanical Circulatory Support Developing a low-profile, high-flow percutaneous ventricular assist device (pVAD) for high risk coronary intervention and cardiogenic shock. Clinical Need Percutaneous ventricular assist devices (pVADs) are placed to provide temporary mechanical support, assisting the native pumping action of
- Sparrow Quantum — Sparrow Quantum, a global leader in quantum photonic chip technology. Explore innovative solutions driving advancements in quantum computing, communication, and beyond. Stay ahead with cutting-edge technologies shaping the future.
- Tribune Therapeutics — Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. It was founded in 2020 with funding from HealthCap and Novo Seeds.
Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companiesin the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.
Show more
Investment focus
- Health Care, Biotechnology, Medical
- Series B, Series A, Series C
- China, United States, Hong Kong
Portfolio highlights
- AusperBio — AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treata wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases.
- LongBio Pharma — LongBio Pharma is a biotech company that treats patients with an emphasis on complement and allergy diseases.
- Tianchen Biotechnology — Tianchen Biotechnology is a biotech company that specializes in the research, design, development, and sales of ophthalmology-related medical products. It provides complete diagnostic and treatment solutions for ophthalmology.
Renaissance is an investment foundation for pension funds investing in Swiss SMEs. It acts as a partner of the SMEs, participating in companies within the framework of succession planning or company outsourcing and thus promotes the Swiss SME landscape by maintaining and creating jobs.The firm was founded in 1997 and is headquartered in Lausanne,Vaud.
Show more
Investment focus
- Medical, Software, Health Care
- Series B, Series C, Seed
- Switzerland
Portfolio highlights
- Anergis — Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne inSwitzerland.
- GlassIG — It is an independent software vendor. Our aim is to provide market leading and cost effective Information Governance for everyone. At They are proud of our mission to serve and inspire our customers to establish and operate an effective Information Governance solution.
- Beqom — beqom is a Total Compensation Management Software Solution focused exclusively on managing compensation & performance for HR & Sales.
Blue Owl is a leading asset management firm offering alternative investment solutions in private credit, GP stakes, and real assets.
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Debt Financing, Post-IPO Equity, Series B
- United States, United Kingdom, Canada
Portfolio highlights
- Neuron23 — Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease.
- Baker Tilly — Since they formed in 1987, they have grown to a top ten practice with over 100 employees in Ireland. they are known for building long term, personal relationships with their clients. they know that their success is measured by their clients’ success, if they are achieving their goals they know they’re doing their job.As a top ten firm, theyoffer access to service line specialists, sector specific experience and can leverage true international expertise through their membership of the Baker Tilly International network. they offer solutions.Their client’s requirements are their strategic drivers. They keep us striving to do more, to go further, to realise the very best outcome for their business challenges. In turn, they deliver hard-working solutions, innovative strategies and expert advice, borne of industry experience and rigorous thought.They give advice they believe in.
- Juniper Square — Juniper Square is the leading provider of investment management software and solutions for real estate and private equity fundraising, investor reporting, and more.
Igor Fish
Show more
Investment focus
- Medical, Health Care, Life Science
- Series A
- Switzerland
Portfolio highlights
- NewBiologix — NewBiologix operates as a technology innovation company, develops a proprietary and breakthroughDNA integration platform for the advanced engineering of human and mammaliancell lines.
Privilege Ventures is the venture capital arm of Privilège Management and invest in seed and early stage companies. Geographical focus is Switzerland and the rest of Europe. Focus sectors are industrial-tech, med-tech, wearables and in general ICT.
Show more
Investment focus
- Health Care, Hardware, Software
- Seed, Series A, Funding Round
- Switzerland, France
Portfolio highlights
- Wyth — Wyth makes technologies that help humans create meaningful relationships by bringing emotions, stories and connections beyond the interface.
- Smeetz — Smeetz is the future of a unified, data-driven and dynamic pricing-oriented commerce for attractions and cultural venues.
- Avelo — Our mission is to save lives by bringing fast and actionable infectious disease diagnosis closer to the patient. Avelo's solution is a breath collection device. It works with existing molecular tests to detect multiple respiratory tract infections causing pneumonia
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, United Kingdom, Canada
Portfolio highlights
- Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
- Draig Therapeutics — Draig Therapeutics is a clinical-stage biopharmaceutical startup dedicated to creating next-generation treatments for serious neuropsychiatric illnesses.
- ORIC Pharmaceuticals — ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate,ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeuticsacross a variety of solid tumors. ORIC’s second product candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens. Beyond these two product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC’s scientific founders, Charles Sawyers, MD, and Scott Lowe, PhD, have long records of discovering novel targets in cancer that have led to innovative treatments.
JFG Life Sciences Foundation is a non-profit foundation.
Show more
Investment focus
- Biopharma, Health Care, Biotechnology
- Seed
- Switzerland
Portfolio highlights
- Invasight — Invasight is a clinical biotech company that focused on revolutionizing cell invasion research. The company was founded in 2019 and is headquartered in Zurich, Switzerland.
- NXI Therapeutics — NXI Therapeutics - Creating Tomorrow's Immunotherapies | The beginning of a new era of specificity and safety in the immunosuppressive therapy market
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series A, Series C
- United States, Switzerland, United Kingdom
Portfolio highlights
- Citryll — Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and other human diseases. The company offers formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes that enable doctors to help in the treatment of lupus,vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis.Citryll was established in 2015 and is headquartered in Oss, The Netherlands.
- Rhygaze — Rhygaze develops a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness.
- Alesta Therapeutics — Alesta Therapeutics focused on translating novel targets in the chronic stress response pathways into new therapeutic approaches to treat cancer
FiveT is an independent alternative asset manager established in 2006. Starting in 2021, FiveT set out to finance the foundation of the hydrogen economy.
Show more
Investment focus
- FinTech, Software, Health Care
- Seed, Convertible Note, Initial Coin Offering
- United States, Switzerland
Portfolio highlights
- ZELF — Zelf is a neobank targeting Gen Z to bring financial services to where they live – in messengers. This is the lightest bank with the easiest onboarding process taking up to 60 sec to issue a card, receive and send money without leaving the messenger. We are uniquely offering AI-powered voice control over the most of financial operations, whichmakes us first voice-enabled banking for Gen Z who prefers voice interactions with their devices.
- LimeWire — LimeWire develops peer-to-peer software and solutions for the file sharing industry. It offers LimeWire BASIC and LimeWire PRO, the peer-to-peer file sharing applications which connect to the Gnutella network and enables users to search for and download files through other users; and LimeWire Store, a digital media store. Limewire was founded in2000 and is based in New York, New York. The company operates as a subsidiary of Lime Group LLC.
- PreComb Therapeutics — functional precision medicine, oncology, cancer, discovery, organoid, predictive, ai, 3DTwin, data mining, therapy guidance, automated, immune oncology, 2curex, xilis, usz, dkfz, nct, switzerland
Occident macht Investments in Deep Tech Startups aus den Bereichen Lifesciences, Hightech und Digital. Finanzierung ab Seed-Finanzierungsrunde
Show more
Investment focus
- Health Care, Medical Device, Biotechnology
- Series A, Series C, Funding Round
- Germany, Switzerland
Portfolio highlights
- ReCatalyst — REvolutionizing the way we make fuel cell CATALYSTs
- iThera Medical — Due to its spatiotemporal resolution, penetration depth, sensitivity and specificity, optoacoustic imaging (OAI) can be used for a multitude of applications.
- Lunaphore — Lunaphore Technologies is a spatial biology company, building multiplex immunofluorescence & IHC solutions for discovery and immuno-oncology research
Gaingels is a leading venture investment syndicate in support of diversity, inclusive of the LGBTQIA+ community and allies in the venture capital space.
Show more
Investment focus
- Software, Health Care, Artificial Intelligence
- Seed, Series A, Series B
- United States, Canada, Mexico
Portfolio highlights
- Nava — Nava Benefits is a modern employee benefits brokerage leveraging technology and benefits innovation to tackle the rising costs of healthcare.
- Akash Systems — Akash is a pioneer in thermal management, offering solutions that set the global standard for technology.
- Galileo — Galileo provides high-touch, data-driven, multi-specialty, longitudinal care to a diverse and complex patient population—over the phone, at home, and everywhere in between. Regional and national health plans, employers, and Fortune 500 companies all regard Galileo as the leading solution for improving population health. It aims to use that talentand scientific thinking to transform society by solving the most difficult healthcare problems while also bringing patients and providers closer together.
The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Seed
- United States, Germany, Belgium
Portfolio highlights
- Nuevocor — Nuevocor is a preclinical-stage biopharmaceutical company focused on developing gene therapy‑based treatments that have the potential to restore cardiac function in diseased hearts.
- Brainomix — Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.
- Aignostics — Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research. Its “explainable” AI overcomes the “black-box” limitations of conventional AI. Based on their patented technology for reverse-engineering the black box, they render diagnostic results explainable in the form of preciseheatmaps and image overlays. These heatmaps allow pathologists to quickly verify the results of the AI, which is crucial, as the pathologist is ultimately responsible for the diagnosis.The company was founded in 2018 and is headquartered in Berlin, Germany.
As a venture capital company, HBM BioVentures is invested globally in some 40 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The companyfocuses on unquoted emerging companies, with two-thirds are invested in private companies that offer high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SIX Swiss Exchange (ticker: HBMN).
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series C, Series A
- United States, Switzerland, China
Portfolio highlights
- Upstream Bio — Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma. Upstream Bio was founded in 2004 and was headquartered in the United States.
- Vicore Pharma — Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EUand the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal.
- Odyssey Therapeutics — Odyssey Therapeutics is developing innovative medicines to make extraordinary leaps in outcomes for patients with cancer inflammatory diseases
VENTURE We invest across all sectors with specific focus on technology and digital The largest independent more About Us Portfolio [...]
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- Italy, Switzerland, United States
Portfolio highlights
- TES Pharma —
- Iama Therapeutics — At IAMA Therapeutics, we are constantly pushing the boundaries of neuroscience drug discovery to develop new medicines and make a difference in the lives of children suffering from brain disorders and their families. Our purpose is to provide a therapeutic solution to children suffering from neurological conditions and provide their families withthe support they need.
- Valo Therapeutics — Valo Therapeutics is an immunotherapy company that is developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The Valo Tx platform, PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus), was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. It turns oncolytic adenovirusesinto targeted tissue specific cancer vaccines without the need to generate and manufacture multiple genetically modified viruses. The company is also developing PeptiENV, among other neoantigen strategies, in collaboration with Professor Cerullo. PeptiENV is expected to improve the therapeutic response to enveloped oncolytic viruses in the treatment of multiple forms of cancer.
Amboy Street Ventures focuses on sexual health and women’s health technology startups.
Amboy Street Ventures was founded in 2021 and was headquartered in Los Angeles, USA.
Show more
Investment focus
- Health Care, Women's, Biotechnology
- Series A, Seed, Series B
- United States, Sweden, Switzerland
Portfolio highlights
- Juniper Genomics — Juniper Genomics is shaping a better future for aspiring parents by enabling a faster, more successful IVF journey.
- Granata Bio — Granata Bio is a biopharma company focused on women's health and infertility. Our mission and focus is to create access for fertility patients by introducing new therapeutic solutions.
- Gesynta Pharma — Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se
Investors by industry
Consumer
Proptech
Impact
Climate
Gaming
Biotech
FinTech
Marketplace
Community
Health Care
Hardware
Energy
Artificial intelligence
Google
EdTech
Sustainability
Venture Capital
Real Estate
Photography
Clean Energy
Education
B2B
Financial Services
Big Data
Payments
Finance
Organic Food
Food and Beverage
Web3
Infrastructure
Retail
Beauty
Publishing
Video Games
Music
Art
Wellness
Franchise
Mobile
Local
Digital Media
Legal
Android
eSports
Enterprise Software
Sports
Manufacturing
Email
Medical
Social Network
Social Media
Internet
Construction
Hospitality
Platforms
Biotechnology
Cannabis
Mobile Advertising
Travel
Fitness
Recruiting
Crowdfunding
Social
Medical Device
Automotive
Wine And Spirits
CleanTech
Mobile Apps
Transportation
InsurTech
Enterprise
LGBT
Fashion
Oil and Gas
Life Science
Theatre
Film
Non Profit
Renewable Energy
SaaS
Sporting Goods
Restaurants
Social Impact
Celebrity
Software
Cryptocurrency
Machine Learning
Agriculture (agtech)
Media (entertainment)
Facebook
Blockchain
Investors by country
Canada
Germany
United Kingdom
Ireland
South Korea
India
Australia
New Zealand
United States
Middle East
Brazil
LATAM
Qatar
Indonesia
Belarus
Chile
Belgium
Hong Kong
Finland
Ghana
Georgia
Ethiopia
Gibraltar
Faroe Islands
Denmark
Egypt
Estonia
Asia
Costa Rica
Hungary
Greece
Europe
Barbados
Croatia
Spain
Belize
Bahrain
Czech Republic
South Africa
Algeria
Singapore
Ecuador
Bulgaria
Armenia
Saudi Arabia
Bermuda
France
Kuwait
Malta
Sri Lanka
Morocco
Nicaragua
Mali
China
Lithuania
Peru
Lebanon
Jersey
Norway
Africa
Myanmar
Mauritius
Liberia
Mexico
Malaysia
Oceania
Liechtenstein
Philippines
Italy
Japan
Israel
Panama
Vietnam
Poland
Dominican Republic
Senegal
Nigeria
Sierra Leone
Tunisia
Togo
Iraq
Serbia
Azerbaijan
Bahamas
Turkey
San Marino
Iceland
Thailand
Uzbekistan
Taiwan
Namibia
Sweden
United Arab Emirates
Tanzania
Slovenia
Jamaica
El Salvador
Honduras
Portugal
Bolivia
Tajikistan
Ukraine
Puerto Rico
Isle of Man
Uganda
Luxembourg
Venezuela
Uruguay
Zambia
Albania
Zimbabwe
Rwanda
Russian Federation
Pakistan
Kenya
Grenada
Jordan
Bangladesh
Argentina
Romania
Kazakhstan
Cayman Islands
Cambodia
Latvia
Cyprus
Oman
Cameroon
Austria
Switzerland
Colombia
Guatemala
Seychelles
Marshall Islands
Investors in Switzerland by industry
Crowdfunding
Venture Capital
Film
Transportation
eSports
Cryptocurrency
Finance
Food and Beverage
Medical
Wellness
Fitness
Medical Device
Email
Hardware
Internet
Social Media
Social Network
Digital Media
Manufacturing
Music
Android
Mobile
Blockchain
Construction
Software
Legal
Enterprise Software
Sports
Automotive
Hospitality
Travel
InsurTech
Biotechnology
Recruiting
Platforms
Mobile Advertising
FinTech
Enterprise
Consumer
Health Care
EdTech
Climate
Energy
Sustainability
Proptech
SaaS
Marketplace
Community
Artificial intelligence
Gaming
Mobile Apps
Fashion
Web3
B2B
Life Science
Sporting Goods
Publishing
Education
Clean Energy
Renewable Energy
Financial Services
Real Estate
Beauty
Payments
Oil and Gas
CleanTech
Organic Food
Impact
Social Impact
Social
Restaurants
Infrastructure
Non Profit
Agriculture (agtech)
Machine Learning
Media (entertainment)
Biotech
Video Games
Big Data
Retail